Overview

  • Product nameAnti-C3a / C3a des Arg antibody [K13/16]
    See all C3a / C3a des Arg primary antibodies
  • Description
    Mouse monoclonal [K13/16] to C3a / C3a des Arg
  • SpecificityDoes not cross react with C4a or C5a.
  • Tested applicationsSuitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified) corresponding to Human C3a/ C3a des Arg.

  • EpitopeRecognizes an epitope present on human C3, C3a and C3a(desArg).
  • General notes

    Effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 15mM Sodium Azide
    Constituents: 0.5M Sodium chloride, 0.01M PBS, pH 7.4
  • Concentration information loading...
  • PurityProtein A purified
  • Primary antibody notesEffectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay.
  • ClonalityMonoclonal
  • Clone numberK13/16
  • IsotypeIgG1
  • Light chain typekappa
  • Research areas

Associated products

Applications

Our Abpromise guarantee covers the use of ab36385 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/32000.
WB Use at an assay dependent concentration. Predicted molecular weight: 75, 110 kDa.

In vivo, human C3 exists as a 185kDa protein, formed of two smaller proteins linked together via a disulfide bond. In Western blot the proteins will separate and be detected as bands at molecular weights of approximately 75kDa and 110kDa.

Target

  • FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similaritiesContains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational
    modifications
    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acylation stimulating protein antibody
    • Acylation stimulating protein cleavage product antibody
    • ASP antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • CO3_HUMAN antibody
    • Complement C3c alpha'' chain fragment 2 antibody
    • Complement component 3 antibody
    • Complement factor 3 antibody
    • Plp antibody
    see all

Anti-C3a / C3a des Arg antibody [K13/16] images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the of veins of nephritis.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the veins.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the lumen of veins.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/75. Strong staining is visible in the of veins of nephritis.

References for Anti-C3a / C3a des Arg antibody [K13/16] (ab36385)

This product has been referenced in:
  • Elsner J  et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24:518-22 (1994). Read more (PubMed: 8125125) »
  • Elsner J  et al. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83:3324-31 (1994). Read more (PubMed: 8193368) »

See all 4 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab36385.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"